Cisplatin and radiotherapy in the treatment of locally advanced head and neck cancer: A review of their cooperation

Acta Oncologica

Volumn 42, Issue 4, 2003, Pages 315-325

  Marcu, Loredana ^a,b   Van Doorn, Tim ^a,b   Olver, Ian ^a,b  

^a UNIVERSITY OF ADELAIDE   (Australia)

^b ROYAL ADELAIDE HOSPITAL   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

CELLS; CHEMOTHERAPY; PATIENT TREATMENT; RADIOTHERAPY; TOXICITY; TUMORS;

CLINICAL TRIALS;

ONCOLOGY;

CISPLATIN; TIRAPAZAMINE;

ADVANCED CANCER; BLOOD TOXICITY; CANCER CHEMOTHERAPY; CANCER PALLIATIVE THERAPY; CANCER RADIOTHERAPY; CANCER RESISTANCE; CANCER SURVIVAL; CHEMOTHERAPY INDUCED EMESIS; CLINICAL TRIAL; DOSE RESPONSE; DRUG FATALITY; DRUG MEGADOSE; ESOPHAGITIS; GASTROINTESTINAL TOXICITY; HEAD AND NECK CANCER; HEARING LOSS; HUMAN; KIDNEY FAILURE; LOW DRUG DOSE; MONOTHERAPY; NAUSEA; NEPHROTOXICITY; NEUROTOXICITY; NONHUMAN; OTOTOXICITY; PRIORITY JOURNAL; RADIOBIOLOGY; RADIOSENSITIVITY; REVIEW; SIDE EFFECT; SQUAMOUS CELL CARCINOMA; STOMATITIS; TOXICITY; TREATMENT OUTCOME; WEIGHT REDUCTION; XEROSTOMIA;

ANTINEOPLASTIC AGENTS; CISPLATIN; CLINICAL TRIALS; COMBINED MODALITY THERAPY; DRUG ADMINISTRATION SCHEDULE; HEAD AND NECK NEOPLASMS; HUMANS; NEOPLASM METASTASIS; RADIOTHERAPY, ADJUVANT; SALVAGE THERAPY;

EID: 0037825846     PISSN: 0284186X     EISSN: None     Source Type: Journal    
DOI: 10.1080/02841860310004364     Document Type: Review

References (56)

1. Rosenberg B, van Camp L, Krigas T. Inhibition of cell division in Escherichia coli by electrolysis products from a platinum electrode. Nature 1965; 205: 698-9.
2. Tannock IF, Hill RP. The basic science of oncology, 3rd ed. McGraw-Hill, 1998: 338-9.
3. Jeremic B, Shibamoto Y, Stanisavljevic B, et al. Radiation therapy alone or with concurrent low-dose daily either cisplatin or carboplatin in locally advanced unresectable squamous cell carcinoma of the head and neck: a prospective randomized trial. Radiother Oncol 1997; 43: 29-37.
4. Choi KN, Rotman M, Aziz H, et al. Concomitant infusion cisplatin and hyperfractionated radiotherapy for locally advanced nasopharyngeal and paranasal sinus tumors. Int J Radiat Oncol Biol Phys 1997; 39: 823-9.
5. Jeremic B, Shibamoto Y, Milicic B, et al. Hyperfractionated radiation therapy with or without concurrent low-dose daily cisplatin in locally advanced squamous cell carcinoma of the head and neck: a prospective randomized trial. J Clin Oncol 2000; 18: 1458-64.
6. Yoshikawa A, Saura R, Matsubara T, et al. A mechanism of cisplatin action: antineoplastic effect through inhibition of neovascularization. Kobe J Med Sci 1997; 43: 109-20.
7. Prestayko AW, Crooke ST, Carter SK. Cisplatin - current status and new developments. New York: Academic Press; 1980.
8. Reed E, Kohn KW. Platinum analogues. In: Chabner B, Collins JM, eds. Cancer chemotherapy-principles and practice. Philadelphia: Lippincott, 1990.
9. Jacobs C, Bertino JR, Goffinet DR, et al. Twenty-four-hour infusion of cis-platinum in head and neck cancers. Cancer 1978; 42: 2135-40.
10. Creagan E, O'Fallon J, Woods J, et al. Cis-diamminedichloroplatinum (II) administered by 24-hour infusion in the treatment of patients with advanced upper aerodigestive cancer. Cancer 1983; 51: 2020-3.
11. Veronesi A, Zagonel V, Tirelli U, et al. High-dose versus low-dose cisplatin in advanced head and neck squamous carcinoma: a randomized study. J Clin Oncol 1985; 3: 1105-8.
12. Sako K, Razack MS, Kalnins I. Chemotherapy for advanced and recurrent squamous cell carcinoma of the head and neck with high and low dose cis-diamminedichloroplatinum. Am J Surg 1978; 136: 529-33.
13. Vermorken JB, Kapteijn TS, Hart AA, et al. Ototoxicity of cis-diamminedichloroplatinum (II): influence of dose, schedule and mode of administration. Eur J Cancer Clin Oncol 1983; 19: 53-8.
14. Planting AS, de Mulder PH, de Graeff A, et al. Phase II study of weekly high-dose cisplatin for six cycles in patients with locally advanced squamous cell carcinoma of the head and neck. Eur J Cancer 1997; 33: 61-5.
15. Yan R, Durand RE. The response of hypoxic cells in SCCVII murine tumors to treatment with cisplatin and x-rays. Int J Radiat Oncol Biol Phys 1991; 20: 271-4.
16. Dewit L. Combined treatment of radiation and cis-diamminedichloroplatinum (II): a review of experimental and clinical data. Int J Radiat Oncol Biol Phys 1987; 13: 403-26.
17. Coughlin CT, Richmond RC. Biologic and clinical developments of cisplatin combined with radiation: concepts, utility, projections for new trials, and the emergence of carboplatin. Semin Oncol 1989; 16: 31S-43S.
18. Sharma VM, Wilson WR. Radiosensitization of advanced squamous cell carcinoma of the head and neck with cisplatin during concomitant radiation therapy. Eur Arch Otorhinolaryngol 1999; 256: 462-5.
19. Sorenson CM, Barry MA, Eastman A. Analysis of events associated with cell cycle arrest at G2 phase and cell death induced by cisplatin. J Natl Cancer Inst 1990; 82: 749-54.
20. Sorenson CM, Eastman A. Mechanism of cis-diamminedichloroplatinum (II)-induced cytotoxicity: role of G2 arrest and DNA double-strand breaks. Cancer Res 1988; 48: 4484-8.
21. Sorenson CM, Eastman A. Influence of cis-diamminedichlor-oplatinum (II) on DNA synthesis and cell cycle progression in excision repair proficient and deficient Chinese hamster ovary cells Cancer Res 2002; 48: 6703-7.
22. Clamon G, Baatz L, Hoffman H, et al. Neurotoxicity in a phase I trial of continuous-infusion cisplatin with hyperfractionated radiotherapy for locally advanced head and neck cancer. Head Neck 1996; May/June: 236-41.
23. Al-Sarraf M, Pajak T, Marcial V, et al. Concurrent radiotherapy and chemotherapy with cisplatin in inoperable squamous cell carcinoma of the head and neck. An RTOG study. Cancer 1987; 59: 259-65.
24. Harrison L, Pfister D, Fass D, et al. Concomitant chemotherapy-radiation therapy followed by hyperfractionated radiation therapy for advanced unresectable head and neck cancer. Int J Radiat Oncol Biol Phys 1991; 21: 703-8.
25. Crissman J, Pajak T, Zarbo R, et al. Improved response and survival to combined cisplatin and radiation in non-keratinized squamous cell carcinoma of the head and neck. An RTOG study of 114 advanced stage tumors. Cancer 1987; 59: 1397.
26. Marcial V, Pajak T, Mohiuddin M, et al. Concomitant cisplatin chemotherapy and radiotherapy in advanced mucosal squamous cell carcinoma of the head and neck. Cancer 1990; 66: 1861-8.
27. Arias F, Dominguez M, Illarramendi J, et al. Split hyperfractionated accelerated radiation therapy and concomitant cisplatin for locally advanced head and neck carcinomas: a preliminary report. Int J Radiat Oncol Biol Phys 1995; 33: 675-82.
28. Fountzilas G, Skarlos D, Kosmidis P, et al. Radiation therapy and concurrent cisplatin administration in locally advanced head and neck cancer. A Hellenic co-operative oncology group study. Acta Oncol 1994; 33: 825-30.
29. Gasparini G, Pozza F, Recher G, et al. Simultaneous cisplatinum and radiotherapy in inoperable or locally advanced squamous cell carcinoma of the head and neck. Oncology 1991; 48:270-6.
30. Glaser MG, Leslie MD, O'Reilly SM, et al. Weekly cisplatinum concomitant with radical radiotherapy in the treatment of advanced head and neck cancer. Clin Oncol 1993; 5: 286-9.
31. Robbins KT, Kumar P, Regine W, et al. Efficacy of targeted supradose cisplatin and concomitant radiation therapy for advanced head and neck cancer: The Memphis experience. Int J Radiat Oncol Biol Phys 1997; 38: 263-71.
32. Huguenin P, Glanzmann C, Taussky D, et al. Hyperfractionated radiotherapy and simultaneous cisplatin for stage-III and -IV carcinomas of the head and neck. Long-term results including functional outcome. Strahlenther Onkol 1998; 174: 397-402.
33. Serin M, Erkal HS, Cakmak A. Radiation therapy and concurrent cisplatin in management of locoregionally advanced nasopharyngeal carcinomas. Acta Oncol 1999; 38: 1031-5.
34. National Cancer Institute board of scientific advisors. Report of the National Cancer Institute clinical trials implementation committee, Bethesda, USA.
35. Trotti A. Update on toxicity in head and neck cancer: mechanism, grading, & interventions. Http://www.medscape.-com/Medscape/oncology/ TreatmentUpdate/2000/tu04/tu04-02.html
36. Fontanesi J, Beckford NS, Lester EP, et al. Concomitant cisplatin and hyperfractionated external beam irradiation for advanced malignancy of the head and neck. Am J Surg 1991; 162: 393-6.
37. Bachaud JM, Chatelut E, Canal P, et al. Radiotherapy with concomitant continuous cisplatin infusion for unresectable tumors of the upper aerodigestive tract: results of a phase I study. Am J Clin Oncol 1997; 20: 1-5.
38. Leipzig B. Cisplatin sensitization to radiotherapy of squamous cell carcinomas of the head and neck. Am J Surg 1983; 146: 462-5.
39. Jakobsen A, Mortensen LS. On the importance of sensitivity to the dose-effect relationship in chemotherapy. Acta Oncol 1997; 36: 375-81.
40. Coldman AJ, Goldie JH. Role of mathematical modeling in protocol formulation in cancer chemotherapy. Cancer Treat Rep 1985; 69: 1041-5.
41. Birkhead B, Gregory WM, Slevin M, et al. Evaluating and designing cancer chemotherapy treatment using mathematical models. Eur J Cancer 1986; 22: 3-8.
42. de Graeff A, Slebos RJ, Rodenhuis S. Resistance to cisplatin and analogues: mechanisms and potential clinical implications. Cancer Chemother Pharmacol 1988; 22: 325-32.
43. Perez RP. Cellular and molecular determinants of cisplatin resistance. Eur J Cancer 1998; 34: 1535-42.
44. Robbins KT, Storniolo AM, Hryniuk WM, et al. Decadose' effects of cisplatin on squamous cell carcinoma of the upper aerodigestive tract. II. Clinical studies. Laryngoscope 1996; 106: 37-42.
45. Ferguson PJ, Currie C, Vincent MD. Enhancement of platinum-drug cytotoxicity in a human head and neck squamous cell carcinoma line and its platinum-resistant variant by liposomal amphotericin B and phospholipase A2-II. Mol Pharmacol 1999; 27: 1399-405.
46. Peters L, Withers HR, Thames HD, et al. The problem: tumor radioresistance in clinical radiotherapy. Int J Radiat Oncol Biol Phys 1982; 8: 101-8.
47. Wallner KE, Li GC. Effect of cisplatin resistance on cellular radiation response. Int J Radiat Oncol Biol Phys 1987; 13: 587-91.
48. Lartigau E, Stern S, Guichard M. In vitro oxygen-dependent survival of 2 human cell lines after radiation combined with tirapazamine and cisplatin. Cancer Radiother 2000; 4: 217-22.
49. Dorie MJ, Kovacs MS, Gabalski EC, et al. DNA damage measured by the comet assay in head and neck cancer patients treated with tirapazamine. Neoplasia 1999; 1: 461-7.
50. Peters L, Withers HR. Applying radiobiological principles to combined modality treatment of head and neck cancer - the time factor. Int J Radiat Oncol Biol Phys 1997; 39: 831-6.
51. Begg AC, Haustermans K, Hart AAM, et al. The value of pre-treatment cell kinetic parameters as predictors for radiotherapy outcome in head and neck cancer: a multicenter analysis. Radiother Oncol 1999; 50: 13-23.
52. Bartelink H, Begg A, Martin JC, et al. Towards prediction and modulation of treatment response. Radiother Oncol 1999; 50: 1-11.
53. Withers HR, Taylor JMG, Maciejewski B. The hazard of accelerated tumor clonogen repopulation during radiotherapy. Acta Oncol 1988; 27: 131-46.
54. Schwachöfer JHM, Crooijmans RP, Hoogenhout J, et al. Effectiveness in inhibition of recovery of cell survival by cisplatin and carboplatin: influence of treatment sequence. Int J Radiat Oncol Biol Phys 1991; 20: 1235-41.
55. Glynne-Jones R, Sebag-Montefiore D. Chemoradiation schedules - what radiotherapy? Eur J Cancer 2002; 38: 258-69.
56. Marcu L, van Doorn T, Zavgorodni S, et al. Growth of a virtual tumour using probabilistic methods of cell generation. Aust Phys Eng Sci Med 2002; 25: 155-61.